Inhibition of human liver and duodenum sulfotransferases by drugs and dietary chemicals: A review of the literature

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 9, 2004, Pages 488-495

  Pacifici, G M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Flavonoids; Gut; Liver; Mefenamic acid; Nonsteroidal anti inflammatory drugs; Platelets; Salicylic acid; Sulfotransferase

Indexed keywords

3 HYDROXYFLAVONE; APOMORPHINE; ARYL SULFOTRANSFERASE; DICLOFENAC; DIFLUNISAL; DOPAMINE; EPICATECHIN; EPIGALLOCATECHIN GALLATE; ESTROGEN SULFOTRANSFERASE; FLAVONE DERIVATIVE; FLAVONOID; HYDROXYL GROUP; IBUPROFEN; INDOMETACIN; INTESTINE ENZYME; KETOPROFEN; KETOROLAC; LIVER ENZYME; MEFENAMIC ACID; MINOXIDIL; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PRIMULETIN; QUERCETIN; RESVERATROL; SALBUTAMOL; SALICYLIC ACID; SULFOTRANSFERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG MECHANISM; DRUG SULFATION; DUODENUM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBSTRATE; FOOD DRUG INTERACTION; FRUIT; HUMAN; IC 50; INFORMATION RETRIEVAL; LIVER; MEDICAL LITERATURE; MICHAELIS CONSTANT; REVIEW; SYSTEMATIC REVIEW; VEGETABLE; WINE;

EID: 4544300103     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42488     Document Type: Review

References (44)

1. Benet LZ, Oie S, Schwartz JB 1996 Design and optimisation of dosage regimens, pharmacokinetic data. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds) The pharmacological basis of therapeutics (9th ed). McGraw-Hill, New York, pp 1707-1793
2. Bernareggi A 1998 Clinical pharmacokinetics of minesulide. Clin Pharmacokinet 35: 247-274
3. Boberg EW, Miller EC, Miller JA, Poland A, Liem A 1983 Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1′-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1′-hydroxysafrole in mouse liver. Cancer Res 43: 5163-5173
4. Bonham Carter SM, Rein G, Glover V, Sandler M 1983 Human platelet phenolsulphotransferase M and P: substrate specificities and correlation with in vivo sulphoconjugation of paracetamol and salicylamide. Br J Clin Pharmacol 15: 323-330
5. Campbell NRC, Van Loon JA, Weinshilhoum RM 1987 Human liver phenol sulfotransferase: assay conditions, biochemical properties and partial purification of isoenzymes of the thermostabile form. Biochem Pharmacol 36: 1435-1446
6. Cappiello M, Giuliani L, Pacifici GM 1990 Differential distribution of phenol and catechol sulphotransferase in human liver and intestinal mucosa. Pharmacology 40: 64-76
7. Coughtrie MWH, Johnston LE 2001 Interactions between dietary chemicals and human sulfotransferases - molecular mechanism and clinical significance. Drug Metab Dispos 29: 522-528
8. De Santi C, Pietrabissa A, Spsinsi R, Mosca F, Pacifici GM 2000a Sulfation of resveratrol, a natural product present in grapes and wine, in the liver and duodenum. Xenobiotica 30: 609-617
9. De Santi C, Pietarbissa A, Spisni R, Mosca F, Pacifici GM 2000b The sulfation of resveratrol, a natural compound present in wine, is inhibited by natural flavonoids. Xenobiotica 30: 857-866
10. De Santi C, Pietarbissa A, Mosca F, Rune A Pacifici GM 2002 Inhibition of phenol sulfotransferase (SULT1A1) by quercetin in human adult and fetal livers. Xenobiotica 32: 363-368
11. Eaton EA, Walle UK, Lewis AJ, Hudson T, Wilson AA, Walle T 1996 Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Drug Metab Dispos 24: 232-237
12. Funkhouser EM, Sharp GB 1995 Aspirin and reduced risk of esophageal carcinoma. Cancer 76: 1116-1119
13. Greenberg ER, Baron JA, Freeman DH, Mandel JS, Hailer R 1993 Reduced risk of large-bowel adenomas among aspirin users. J Natl Can Inst 85: 912-916
14. Harris RM, Waring RH 1996 Dietary modulation of human platelet phenolsulphotransferase activity. Xenobiotica 26: 1241-1247
15. Harris RM, Hawker RJ, Langman MJS, Singh S, Waring RH 1998 Inhibition of phenolsulphotransferase by salicylic acid: a posible mechanism by which aspirin may reduce carcinogenesis. Gut 42: 272-275
16. Heath CW, Thun MJ, Greenberg ER, Levin B, Marnett LJ 1994 Nonsteroidal antiinflammatory drugs and human cancer. Cancer 74: 2885-2888
17. Hollman PC, van Trijp JMP, Buysman MN, van der Gaag MS, Mengelers MJ, de Vries JH, Katan MB 1997 Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. Febs Lett 418: 152-156
18. Littlewood JT, Glover V, Sandler M 1985 Red wine contains a potent inhibitor of phenolsulphotransferase. Br J Clin Pharmacol 19: 275-278
19. Marchetti F, De Santi C, Vietri M, Pietrabissa A, Spisni F, Mosca F, Pacifici GM 2001 Differential inhibition of human liver and duodenum sulfotransferase activities by quercetin, a flavonoid present in vegetables, fruit and wine. Xenobiotica 31: 841-847
20. McCall JH, Aiken JW, Chigester CG, DuCarme DW, Wendling MG 1983 Pyrimidine and triazine 3-oxide sulfates: a new familiy of vasodilators. J Med Chem 26: 1791-1793
21. Miller JA, Miller EC 1986 Electrophilic sulfuric acid ester metabolites as ultimate carcinogens. In: Kocsis JJ, Jollow DJ, Witmer CM, Nelson JO, Snyder R (eds) Biological Reactive Intermediates III. Plenum Press, New York
22. Morgan DJ, Paull JD, Richmond BA, Wilsom-Evered E, Ziccone SP 1986 Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugation. Br J Clin Pharmacol 22: 587-593
23. Neuvonen PJ, Kivisto KT 1988 Effect of magnesium hydroxyde on the absorption of tolfenamic and mefenamic acids. Eur J Clin Pharmacol 35: 495-501
24. Otake Y, Nolan AL, Walle UK, Walle T 2000 Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Ster Biochem Mol Biol 73: 265-270
25. Pacifici GM, De Santi C 1995 Human sulphotransferase classification and metabolic profile of the major isoforms. The point of view of the clinical pharmacologist. In: Pacifici GM, Fracchia GN (eds) Advances in Drug Metabolism in Man. European Commission, Luxembourg, pp 311-349
26. Pacifici GM, Nottoli R 1995 Placental transfer of drugs administered to the mother. Clin Pharmacokinet 28: 235-269
27. Pacifici GM, Giulianetti B, Quilici MC, Spisni R, Nervi M, Giuliani L, Gomeni R 1997 (-)-Salbutamol sulfation in the human liver and duodenal mucosa: interindividual variability. Xenobiotica 27: 279-286
28. Rao SI, Duffel MW 1991 Inhibition of aryl sulfotransferase by carboxylic acids. Drug Metab Dispos 19: 543-545
29. Riess W, Stierlin H, Degen P 1978 Pharmacokinetics and metabolism of anti-inflammatory agent voltaren. Scand J Rheumatol 22: 17-29
30. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S 1991 A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83: 355-358
31. Scott G, Nierenberg D 1992 Pharmacokinetic data for commonly used drugs. In: Melanoma KL, Morel HF, Hoffman BB, Nierenberg DW (eds) Clinical pharmacology. Basic Principles in Therapeutics (3rd ed). McGraw-Hill, New York, pp 1029-1072
32. Tamura H, Matsui M 2000 Inhibitory effects of green tea and grape juice on the phenol sulfotransferase activity of mouse intestines and human colon carcinoma cell line, Caco-2. Biol Pharmaceut Bull 23: 695-699
33. Thun MJ, Namboodiri MY, Heath CW 1991 Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325: 1593-1596
34. Tsutsumi M, Noguchi O, Okita S 1995 Inhibitory ellicts of sulfation inhibitors on initiation of pancreatic ductal carcinogenesis by N-nitrosobis(2-oxopropyl) amine in hamsters. Carcinogenesis 16: 457-459
35. Viani A, Rizzo G, Carrai M, Pacifici GM 1992 The effect of ageing on plasma albumin and plasma protein binding of diazepam, salicylic acid and digitoxin in healthy subjects and patients with renal impairment. Br J Clin Pharmacol 33: 299-304
36. Vietri M, De Santi C, Pietrabissa A, Mosca F, Pacifici GM 2000a Inhibition of human liver phenol sulfotransferase by nonsteroidal anti-inflammatory drugs. Eur J Clin Pharmacol 56: 81-87
37. Vietri M, De Santi C, Pietrabissa A, Mosca F, Pacifici GM 2000b Fenamates and the potent inhibition of human liver phenol sulphotransferase. Xenobiotica 30: 111-116
38. Vietri M, Pietrabissa A, Spisni R, Mosca F, Pacifici GM 2000c Differential inhibition of hepatic and duodenal sulfation of (-)-salbutamol and minoxidil by mefenamic acid. Eur J Clin Pharmacol 56: 477-479
39. Vietri M, Pietrabissa A, Mosca F, Rane A, Pacifici GM 2001 Human adult and foetal liver sulphotransferase: inhibition by mefenamic acid and salicylic acid. Xenobiotica 31: 153-161
40. Vietri M, Vaglini F, Pietrabissa A, Spisni R, Pacifici GM 2002a Sulfation of R(-)-apomorphine in human liver and duodenum and its inhibition by mefenamic acid, salicylic acid and quercetin. Xenobiotica 32: 587-594
41. Vietri M, Pietrabissa A, Spisni R, Mosca F, Pacifici GM 2002b 7-OH-flavone is sulfated in human liver and duodenum whereas 5-OH-flavone and 3-OH-flavone are potent inhibitors of SULT1A1 activity and 7-OH-flavone sulfiation rate. Xenobiotica 32: 563-571
42. Vietri M, Pietrabissa A, Mosca F, Spisni R, Pacifici GM 2003 Curcumin is a potent inhibitor of phenol sulfotransferase (SULT1A1) in human liver and extrahepatic tissues. Xenobiotica 33: 357-363
43. Walle T, Eaton EA, Walle UK 1995 Quercetin, a potent and specific inhibitor of the human P form phenolsulfotransferase. Biochem Pharmacol 50: 731-734
44. Weinshilboum RM 1986 Phenol sulphotransferase in humans: properties, regulation and function. Fed PROC 45: 2223-2228